MX2022008773A - Profármacos de citocinas il-2 que comprenden un enlazador escindible. - Google Patents
Profármacos de citocinas il-2 que comprenden un enlazador escindible.Info
- Publication number
- MX2022008773A MX2022008773A MX2022008773A MX2022008773A MX2022008773A MX 2022008773 A MX2022008773 A MX 2022008773A MX 2022008773 A MX2022008773 A MX 2022008773A MX 2022008773 A MX2022008773 A MX 2022008773A MX 2022008773 A MX2022008773 A MX 2022008773A
- Authority
- MX
- Mexico
- Prior art keywords
- prodrugs
- cytokine
- cleavable linker
- cleavable
- protease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062961537P | 2020-01-15 | 2020-01-15 | |
| PCT/US2021/013478 WO2021146455A1 (en) | 2020-01-15 | 2021-01-14 | Cytokine il-2 prodrugs comprising a cleavable linker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008773A true MX2022008773A (es) | 2022-10-03 |
Family
ID=74562082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008773A MX2022008773A (es) | 2020-01-15 | 2021-01-14 | Profármacos de citocinas il-2 que comprenden un enlazador escindible. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240043489A1 (https=) |
| EP (1) | EP4090673A1 (https=) |
| JP (1) | JP2023511074A (https=) |
| KR (1) | KR20220128413A (https=) |
| CN (2) | CN116655799A (https=) |
| AU (1) | AU2021208553A1 (https=) |
| BR (1) | BR112022013993A2 (https=) |
| CA (1) | CA3164522A1 (https=) |
| IL (2) | IL294763A (https=) |
| MX (1) | MX2022008773A (https=) |
| WO (1) | WO2021146455A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021016599A1 (en) * | 2019-07-25 | 2021-01-28 | Trutino Biosciences Inc | Il-2 cytokine prodrugs comprising a cleavable linker |
| WO2021207669A1 (en) | 2020-04-10 | 2021-10-14 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| AU2023226005A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Activatable il-18 polypeptides |
| US20240376170A1 (en) | 2023-01-11 | 2024-11-14 | Bright Peak Therapeutics Ag | Conditionally activated proteins and methods of use |
| US20240417436A1 (en) | 2023-01-11 | 2024-12-19 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| EP4704979A1 (en) * | 2023-01-20 | 2026-03-11 | Boehringer Ingelheim International GmbH | Il-12 fc fusion proteins |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| EP2553101A4 (en) * | 2010-04-02 | 2013-09-04 | Univ Rochester | PROTEASE-ACTIVATED CYTOKINES |
| EP3762406A2 (en) * | 2018-03-09 | 2021-01-13 | Askgene Pharma, Inc. | Cytokine prodrugs |
| AU2019271148B9 (en) * | 2018-05-14 | 2025-05-29 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
| AU2019288484B2 (en) * | 2018-06-22 | 2024-06-20 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
-
2021
- 2021-01-14 BR BR112022013993A patent/BR112022013993A2/pt unknown
- 2021-01-14 AU AU2021208553A patent/AU2021208553A1/en active Pending
- 2021-01-14 CN CN202310017475.0A patent/CN116655799A/zh active Pending
- 2021-01-14 US US17/792,976 patent/US20240043489A1/en active Pending
- 2021-01-14 CN CN202180021141.XA patent/CN115298205A/zh active Pending
- 2021-01-14 IL IL294763A patent/IL294763A/en unknown
- 2021-01-14 JP JP2022543432A patent/JP2023511074A/ja active Pending
- 2021-01-14 IL IL294617A patent/IL294617A/en unknown
- 2021-01-14 WO PCT/US2021/013478 patent/WO2021146455A1/en not_active Ceased
- 2021-01-14 EP EP21704141.7A patent/EP4090673A1/en active Pending
- 2021-01-14 MX MX2022008773A patent/MX2022008773A/es unknown
- 2021-01-14 CA CA3164522A patent/CA3164522A1/en active Pending
- 2021-01-14 KR KR1020227028145A patent/KR20220128413A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116655799A (zh) | 2023-08-29 |
| US20240043489A1 (en) | 2024-02-08 |
| IL294763A (en) | 2022-09-01 |
| JP2023511074A (ja) | 2023-03-16 |
| IL294617A (en) | 2022-09-01 |
| BR112022013993A2 (pt) | 2022-10-11 |
| CN115298205A (zh) | 2022-11-04 |
| EP4090673A1 (en) | 2022-11-23 |
| KR20220128413A (ko) | 2022-09-20 |
| CA3164522A1 (en) | 2021-07-22 |
| AU2021208553A1 (en) | 2022-09-08 |
| WO2021146455A1 (en) | 2021-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008773A (es) | Profármacos de citocinas il-2 que comprenden un enlazador escindible. | |
| EP4004026A4 (en) | IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER | |
| WO2019236567A3 (en) | Tumor microenvironment-activated drug-binder conjugated, and uses related thereto | |
| PH12019501056A1 (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
| EP4316524A3 (en) | Camptothecin derivatives | |
| WO2020236841A3 (en) | Antibody drug conjugates having linkers comprising hydrophilic groups | |
| MA40030A (fr) | Conjugués peptide-médicament | |
| IL279400A (en) | CXCR5-targeted linker/active agent conjugates with enzymatically cleavable linkers and an improved activity profile | |
| MY210315A (en) | Cnp prodrugs | |
| SG10201908685QA (en) | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups | |
| NZ608387A (en) | Prodrugs comprising an exendin linker conjugate | |
| NZ744936A (en) | Derivatives of amanita toxins and their conjugation to a cell binding molecule | |
| EP2547306A4 (en) | VIBRATORY APPARATUS | |
| MY200700A (en) | Edb targeting il-12 compositions | |
| MX2023007679A (es) | Aglutinante en estado solido. | |
| NZ786208A (en) | Compounds for the induction of antigen-specific immune tolerance | |
| ZA202001747B (en) | Psma-targeting amanitin conjugates | |
| WO2010053650A3 (en) | Improved feed injector system | |
| MX2025000590A (es) | Anticuerpo anti-trop2 y conjugados del mismo | |
| TW200717050A (en) | Light guide plate | |
| ZA202303252B (en) | Macrophage targeting drug conjugates | |
| MX2021007548A (es) | Adc con enlazadores multiplex de tiol. | |
| HK40074822A (en) | Il-2 cytokine prodrugs comprising a cleavable linker | |
| HK40084774A (en) | Cytokine il-2 prodrugs comprising a cleavable linker | |
| MX2023004320A (es) | Compuestos enlazadores que comprenden enlaces de amida. |